Paxlovid reduces serious risks from Omicron variants - ISS-G20 Laboratorium Repository

Antiviral treatments can help reduce the risk of serious illness and death from SARS-CoV-2, the virus that causes COVID-19. This is particularly true for those who aren’t fully vaccinated. In 2021, a clinical trial found that a combination of the antiviral drugs nirmatrelvir and ritonavir reduced the risk of severe COVID-19 by almost 90% for unvaccinated people. The combination is sold under the name Paxlovid.

Entire content available on: https://www.nih.gov/news-events/nih-research-matters/paxlovid-reduces-serious-risks-omicron-variants